4//SEC Filing
Cherevka Holli 4
Accession 0001209191-18-053316
CIK 0001411906other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 5:27 PM ET
Size
26.0 KB
Accession
0001209191-18-053316
Insider Transaction Report
Form 4
Cherevka Holli
Chief Operating Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−45,000→ 0 totalExercise: $4.72Exp: 2023-04-02→ Common Stock (45,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+30,000→ 30,000 totalExercise: $0.75Exp: 2024-10-06→ Common Stock (30,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−170,000→ 0 totalExercise: $1.03Exp: 2026-07-15→ Common Stock (170,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−35,000→ 0 totalExercise: $4.16Exp: 2023-01-14→ Common Stock (35,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−9,402→ 0 totalExercise: $8.62Exp: 2023-11-08→ Common Stock (9,402 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+9,402→ 9,402 totalExercise: $0.75Exp: 2023-11-08→ Common Stock (9,402 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+45,000→ 45,000 totalExercise: $0.75Exp: 2023-04-02→ Common Stock (45,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−30,000→ 0 totalExercise: $3.43Exp: 2024-10-06→ Common Stock (30,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+170,000→ 170,000 totalExercise: $0.75Exp: 2026-07-15→ Common Stock (170,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+35,000→ 35,000 totalExercise: $0.75Exp: 2023-01-14→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" has been amended to reduce such exercise price to $0.75. There have been no other changes to the terms of the Relevant Options.
- [F2]The stock options have vested and have become fully exercisable.
Documents
Issuer
Ampio Pharmaceuticals, Inc.
CIK 0001411906
Entity typeother
Related Parties
1- filerCIK 0001717673
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 5:27 PM ET
- Size
- 26.0 KB